知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

97 条记录 (耗时 0.022 秒)

    Ibuprofen for symptomatic treatment of diarrheas in HIV patients
    51.
    发明授权
    Ibuprofen for symptomatic treatment of diarrheas in HIV patients 有权

    公开(公告)号：US11969400B2

    公开(公告)日：2024-04-30

    申请号：US17209324

    申请日：2021-03-23

    申请人： Kumara V. Nibhanipudi

    发明人： Kumara V. Nibhanipudi

    IPC分类号： A61K31/4422 ,  A61K31/192 ,  A61P1/12

    CPC分类号： A61K31/192 ,  A61P1/12

    摘要： A method of treating noninfectious diarrhea in an HIV positive subject includes administering a dose of ibuprofen to the HIV positive subject at regular intervals until stool consistency is improved, diarrhea is alleviated, or the number of bowel movements per day are decreased. The dose is 400 mg of ibuprofen administered every 6 hours. The method may additionally include diagnosing the subject with noninfectious diarrhea, determining the subject does not have certain comorbidities, and/or determining that the subject is not taking any non-steroidal anti-inflammatory drugs. The method may additionally include after administering the ibuprofen, administering a clear liquids diet to the subject, administering an electrolyte supplement to the subject, and/or monitoring the subject for any bleeding from the gastrointestinal tract until stool consistency is improved, until diarrhea is alleviated, or until the number of bowel movements per day are decreased.

    ORAL OCTREOTIDE FOR THE TREATMENT OF DISEASE
    56.
    发明公开
    ORAL OCTREOTIDE FOR THE TREATMENT OF DISEASE 审中-公开

    公开(公告)号：US20240016899A1

    公开(公告)日：2024-01-18

    申请号：US18476273

    申请日：2023-09-27

    申请人： Amryt Endo, Inc.

    发明人： Roni MAMLUK ,  Gary PATOU ,  Dana GELBAUM ,  Asi HAVIV

    IPC分类号： A61K38/31 ,  A61P1/16 ,  A61P1/12 ,  A61P13/12 ,  A61K9/00 ,  A61K45/06

    CPC分类号： A61K38/31 ,  A61P1/16 ,  A61P1/12 ,  A61P13/12 ,  A61K9/0053 ,  A61K45/06

    摘要： The present invention relates to oral therapy of a subject suffering from disease e.g. polycystic disease e.g. polycystic kidney disease or polycystic liver disease or PCOS or hypotension especially neurogenic orthostatic hypotension and postprandial hypotension, or intractable diarrhea or neuroendocrine tumors or carcinoid syndrome. The method of treatment comprises oral administration to the subject of a therapeutically effective amount of an oral somatostatin receptor ligand (SRL) e.g. oral octreotide. Combination therapy of oral SRLs with other drugs is also envisaged, e.g. octreotide in combination with a therapeutically effective amount of a second therapeutic agent and optionally in combination with a therapeutically effective amount of a third therapeutic agent.

    METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING ANTI-TL1A ANTIBODIES
    59.
    发明公开
    METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING ANTI-TL1A ANTIBODIES 审中-公开

    公开(公告)号：US20230235070A1

    公开(公告)日：2023-07-27

    申请号：US18002368

    申请日：2021-06-23

    申请人： Pfizer Inc.

    发明人： Mary Lynn BANIECKI ,  Mina HASSAN-ZAHRAEE ,  Kenneth Eugene HUNG ,  Gang LI ,  Li XI ,  Zhan YE

    IPC分类号： C07K16/28 ,  A61P1/12

    CPC分类号： C07K16/2875 ,  A61P1/12

    摘要： The present invention relates to a method for treating inflammatory bowel disease (IBD) in a patient, the method comprising administering to the patient an anti-TNF-like ligand 1A (TL1A) antibody in an induction dosing regimen sufficient to improve signs and symptoms of IBD by at least 12 weeks after the start of treatment with the anti-TL1A antibody, said induction dosing regimen comprising a plurality of individual induction doses, wherein the method further comprises administering to the patient a subsequent maintenance dosing regimen after completion of the induction dosing regimen, said maintenance dosing regimen comprising a plurality of individual maintenance doses separated from each other by at least 2 weeks.